BNP Paribas Exane Upgrades Haleon (NYSE:HLN) to Outperform

Haleon (NYSE:HLN - Get Free Report) was upgraded by investment analysts at BNP Paribas Exane from a "neutral" rating to an "outperform" rating in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $13.40 price target on the stock. BNP Paribas Exane's price target would indicate a potential upside of 17.96% from the company's current price.

HLN has been the subject of a number of other reports. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a report on Friday, May 9th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Stock Up 0.3%

Shares of HLN traded up $0.03 during mid-day trading on Tuesday, hitting $11.36. 24,804,983 shares of the company's stock were exchanged, compared to its average volume of 8,488,277. The stock has a market cap of $51.17 billion, a price-to-earnings ratio of 33.41, a P/E/G ratio of 2.82 and a beta of 0.24. The firm has a fifty day moving average of $10.40 and a two-hundred day moving average of $9.97. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon has a twelve month low of $8.25 and a twelve month high of $11.40.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, sell-side analysts forecast that Haleon will post 0.43 earnings per share for the current year.

Institutional Investors Weigh In On Haleon

A number of institutional investors and hedge funds have recently modified their holdings of HLN. Bartlett & CO. Wealth Management LLC raised its position in shares of Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after purchasing an additional 1,491 shares during the period. Sierra Ocean LLC acquired a new position in Haleon in the 4th quarter valued at about $26,000. Banque Transatlantique SA bought a new position in Haleon in the 1st quarter valued at about $27,000. Opal Wealth Advisors LLC bought a new position in Haleon in the 1st quarter valued at about $29,000. Finally, Ransom Advisory Ltd acquired a new stake in Haleon during the first quarter worth approximately $31,000. 6.67% of the stock is owned by institutional investors.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.